ISOXSUPRINE HYDROCHLORIDE tablet

দেশ: মার্কিন যুক্তরাষ্ট্র

ভাষা: ইংরেজি

সূত্র: NLM (National Library of Medicine)

সক্রিয় উপাদান:

isoxsuprine hydrochloride (UNII: V74TEQ36CO) (Isoxsuprine - UNII:R15UI3245N)

থেকে পাওয়া:

ECI Pharmaceuticals LLC

প্রশাসন রুট:

ORAL

প্রেসক্রিপশন টাইপ:

PRESCRIPTION DRUG

থেরাপিউটিক ইঙ্গিত:

Based on a review of this drug by the National Academy of Sciences-National Research and/or other information, the FDA has classified the indications as follows: - For the relief of symptoms associated with cerebrovascular insufficiency. - In peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's disease) and Raynaud's disease. Final classification of the less-than-effective indications requires further investigation. There are no known contraindications to oral use when administered in recommended doses. Isoxsuprine Hydrochloride, USP should not be given immediately postpartum or in the presence of arterial bleeding.

পণ্য সারাংশ:

Isoxsuprine HCl Tablets, USP 10 mg are white, round, biconvex tablets identified as "I10" debossed on one side and bisected on the other. Isoxsuprine HCl Tablets, USP 20 mg are white, round, biconvex tablets identified as "20" debossed on one side and bisected on the other.

অনুমোদন অবস্থা:

unapproved drug other

পণ্য বৈশিষ্ট্য

ISOXSUPRINE HYDROCHLORIDE- ISOXSUPRINE HYDROCHLORIDE TABLET
ECI PHARMACEUTICALS LLC
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this_
_labeling has not been approved by FDA. For further information about
unapproved_
_drugs, click here._
----------
ISOXSUPRINE HYDROCHLORIDE TABLETS, USP
RX ONLY
DESCRIPTION
Each tablet taken orally contains Isoxsuprine Hydrochloride, USP with
the following
chemical structure:
C
H
NO ∙ HCl
p-Hydroxy-α[1-[(methyl-2-phenoxy-ethyl)amino]ethyl]benzyl alcohol
hydrochloride.
QUANTITATIVE INGREDIENT INFORMATION: Each tablet taken orally contains
10 or 20 mg
Isoxsuprine HCl
PHARMACOLOGICAL CLASS: Peripheral Vasodilator
INDICATIONS
Based on a review of this drug by the National Academy of
Sciences-National Research
and/or other information, the FDA has classified the indications as
follows:
POSSIBLY EFFECTIVE
1. For the relief of symptoms associated with cerebrovascular
insufficiency.
2. In peripheral vascular disease of arteriosclerosis obliterans,
thromboangitis obliterans
(Buerger's disease) and Raynaud's disease.
Final classification of the less-than-effective indications requires
further investigation.
CONTRAINDICATIONS
There are no known contraindications to oral use when administered in
recommended
18
23
3
doses.
Isoxsuprine Hydrochloride, USP should not be given immediately
postpartum or in the
presence of arterial bleeding.
PRECAUTIONS
PEDIATRIC USE
Safety and effectiveness in pediatric patients have not been
established.
ADVERSE REACTIONS
On rare occasion oral administration of the drug has been associated
in time with the
occurrence of hypotension, tachycardia, chest pain, nausea, vomiting,
dizziness,
abdominal distress, and severe rash. If rash appears, the drug should
be discontinued.
Although available evidence suggests a temporal association of these
reactions with
Isoxsuprine Hydrochloride, a causal relationship can be neither
confirmed nor refuted.
Beta Adrenergic receptor stimulants such as Isoxsuprine Hydrochloride
have been used
to in